Reassessing the NTCTCS Staging Systems for Differentiated Thyroid Cancer, Including Age at Diagnosis.
暂无分享,去创建一个
J. Jonklaas | P. Ladenson | D. Steward | J. Brierley | B. Haugen | D. Ross | M. Xing | S. Sherman | M. Skarulis | K. Ain | H. Maxon | D. Cooper | D. McLeod | J. Magner | H. Fein | Danielle R. Litofsky
[1] J. Jonklaas,et al. Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012. , 2015, The Journal of clinical endocrinology and metabolism.
[2] Sung-Bae Kim,et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. , 2015, The New England journal of medicine.
[3] R. Paschke,et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial , 2014, The Lancet.
[4] E. Pribitkin,et al. Is above age 45 appropriate for upstaging well-differentiated papillary thyroid cancer? , 2013, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[5] K. Pathak,et al. The age factor in survival of a population cohort of well-differentiated thyroid cancer , 2013, Endocrine connections.
[6] S. Larson,et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. , 2013, The New England journal of medicine.
[7] D. Chang,et al. A critical analysis of the American Joint Committee on Cancer (AJCC) staging system for differentiated thyroid carcinoma in young patients on the basis of the Surveillance, Epidemiology, and End Results (SEER) registry. , 2012, Surgery.
[8] S. Roman,et al. Aggressive Variants of Papillary Thyroid Cancer: Incidence, Characteristics and Predictors of Survival among 43,738 Patients , 2012, Annals of Surgical Oncology.
[9] J. Jonklaas,et al. The impact of age and gender on papillary thyroid cancer survival. , 2012, The Journal of clinical endocrinology and metabolism.
[10] J. Shah,et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. , 2010, Thyroid : official journal of the American Thyroid Association.
[11] J. Jonklaas,et al. Radioiodine therapy in patients with stage I differentiated thyroid cancer. , 2010, Thyroid : official journal of the American Thyroid Association.
[12] I. Ganly,et al. Tall-cell variant of papillary thyroid carcinoma: a matched-pair analysis of survival. , 2010, Thyroid : official journal of the American Thyroid Association.
[13] G. Gatta,et al. The advantage of women in cancer survival: an analysis of EUROCARE-4 data. , 2009, European journal of cancer.
[14] O. Clark,et al. Changing Management in Patients with Papillary Thyroid Cancer , 2007, Current treatment options in oncology.
[15] J. Jonklaas,et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. , 2006, Thyroid : official journal of the American Thyroid Association.
[16] Sunil J Rao,et al. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2003 .
[17] P. V. Rao,et al. Applied Survival Analysis: Regression Modeling of Time to Event Data , 2000 .
[18] P. Ladenson,et al. Outcome after Treatment of High-Risk Papillary and Non-Hurthle-Cell Follicular Thyroid Carcinoma , 1998, Annals of Internal Medicine.
[19] P. Ladenson,et al. Prospective multicenter study of thyroid carcinoma treatment , 1998 .
[20] E. Bergstralh,et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. , 1993, Surgery.
[21] Max H. Myers,et al. Manual for Staging of Cancer , 1992 .
[22] R. Lloyd,et al. Prognostic Implications of the Tall Cell Variant of Papillary Thyroid Carcinoma , 1988, The American journal of surgical pathology.
[23] B. Caillou,et al. Long‐term results and prognostic factors in patients with differentiated thyroid carcinoma , 1985, Cancer.
[24] F. Harrell,et al. Evaluating the yield of medical tests. , 1982, JAMA.
[25] M. van Glabbeke,et al. A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. , 1979, European journal of cancer.
[26] K. Franssila. Prognosis in thyroid carcinoma , 1975, Cancer.
[27] K. Halnan. Influence of age and sex on incidence and prognosis of thyroid cancer three hundred forty‐four cases followed for ten years , 1966, Cancer.
[28] B. M. Black,et al. Classification and prognosis of thyroid carcinoma. A study of 885 cases observed in a thirty year period. , 1961, American journal of surgery.
[29] J. Hazard,et al. Relationship of the age of the patient to the natural history and prognosis of carcinoma of the thyroid. , 1953, Annals of surgery.
[30] J. Shah,et al. Changing trends in well differentiated thyroid carcinoma over eight decades. , 2012, International journal of surgery.
[31] David Hinkley,et al. Bootstrap Methods: Another Look at the Jackknife , 2008 .
[32] P. Ladenson,et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. , 1998, Thyroid : official journal of the American Thyroid Association.